Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... analyze global next-generation (NGS) sequencing trends and use. ... technology use is expected to increase within the ... are the top criteria for purchasing sequencing instruments. ... technologies. The popularity of RNA-Seq continues to surge, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The custom ... ISPE Boston Product Show 2014. The Boston Area Chapter ... the 23rd annual, day-long event for Wed., Oct. 1 ... promises to be the largest in ISPE Boston’s long ... upward of 3,000 attendees expected. , HOLLOWAY AMERICA ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
Breaking Biology Technology:iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Global Next-generation Sequencing Trends 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... , SOUTH BURLINGTON, Vt ., June 22 As previously ... Property including the patents of the Del-ID system to an Ontario ... is now pleased to announce leadership changes and appointments to QTECH,s Management Team ... of Kitchener, Ontario . , ...
... ... , ... Forza Silicon Corporation announced today that it is in a joint development effort with a ... CMOS image sensors., , , , ,Forza Silicon Corporation Chief Technology Officer, Daniel Van Blerkom, ...
... Researchers at Rensselaer Polytechnic Institute have developed a simple ... nanomaterial graphene. The new technique works at room temperature, ... mass production of graphene. An atom-thick sheet ... unique mechanical and electrical properties and is considered a ...
Cached Biology Technology:delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3Forza Silicon Announces High Dynamic Range CMOS Sensor Development 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 3
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Gut bacteria promote obesity in mice 2Slim cigarette smokers not exposed to more harmful chemicals 2
... valves, can drive experimental samples through a lab-on-a-chip in ... This development could significantly simplify the process of conducting ... research will be published online in the Proceedings ... of July 20. A lab-on-a-chip, or microfluidic ...
... Mice with a defective mitochondrial protein called MCLK1 ... should spell disaster, yet according to a study in ... slower rate and live longer than normal mice. ... aging process; over time, reactive oxygen species produced by ...
... Malaria Research Institute have for the first time produced ... quantity to generate a significant immune response in mice ... vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked ... , as it grows within the mosquito. Sexual development ...
Cached Biology News:Music is the engine of new U-M lab-on-a-chip device 2Vaccine blocks malaria transmission in lab experiments 2
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
ready-to-use solution...
...
Biology Products: